The stock of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) is a huge mover today! About 100,702 shares traded. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has risen 21.47% since September 13, 2016 and is uptrending. It has outperformed by 11.54% the S&P500.The move comes after 8 months negative chart setup for the $64.62 million company. It was reported on Apr, 20 by Barchart.com. We have $1.96 PT which if reached, will make NASDAQ:IPCI worth $3.88M less.
Vaughan David Investments Inc increased National Grid Plc (NGG) stake by 4.48% reported in 2016Q4 SEC filing. Vaughan David Investments Inc acquired 11,170 shares as National Grid Plc (NGG)’s stock declined 17.94%. The Vaughan David Investments Inc holds 260,562 shares with $15.20 million value, up from 249,392 last quarter. National Grid Plc now has $47.07 billion valuation. The stock declined 0.58% or $0.37 reaching $63.72 on the news. About 278,948 shares traded. National Grid plc (ADR) (NYSE:NGG) has declined 7.40% since September 13, 2016 and is downtrending. It has underperformed by 17.32% the S&P500.
Vaughan David Investments Inc decreased Cisco Systems Inc (NASDAQ:CSCO) stake by 19,265 shares to 1.01 million valued at $30.52 million in 2016Q4. It also reduced Intl Business Machines Corp (NYSE:IBM) stake by 5,982 shares and now owns 153,512 shares. Honeywell Internatl Inc (NYSE:HON) was reduced too.
Among 12 analysts covering National Grid (NYSE:NGG), 6 have Buy rating, 1 Sell and 5 Hold. Therefore 50% are positive. National Grid had 15 analyst reports since September 18, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital with “Overweight” on Thursday, May 19. The company was upgraded on Friday, September 18 by Macquarie Research. The stock of National Grid plc (ADR) (NYSE:NGG) earned “Sector Perform” rating by RBC Capital Markets on Friday, July 29. As per Monday, January 30, the company rating was upgraded by RBC Capital Markets. RBC Capital Markets upgraded National Grid plc (ADR) (NYSE:NGG) on Thursday, November 19 to “Outperform” rating. The stock has “Hold” rating by Argus Research on Thursday, April 7. The rating was upgraded by Berenberg on Friday, January 20 to “Buy”. Investec upgraded the stock to “Buy” rating in Friday, January 13 report. On Tuesday, November 29 the stock rating was initiated by Goldman Sachs with “Sell”. As per Wednesday, September 7, the company rating was downgraded by Bernstein.
Intellipharmaceutics International Inc is a Canada pharmaceutical firm engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has market cap of $64.62 million. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It currently has negative earnings. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular.
